Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
CorMedix reported Q2 2026 consolidated revenue of $101.9 million, more than doubling the prior year’s $39.7 million, supported by strong DefenCath sales and the Melinta portfolio. The company delivered net income of $26.0 million, or $0.29 per diluted share, and raised its full-year adjusted EBITDA guidance to $125-$140 million while maintaining revenue expectations. Commercial momentum continued with a new multi-year supply agreement covering all top 5 U.S.
Key figures
- Eps
- 0.29
- Revenue
- 101900000
- Guidance
- FY 2026 consolidated revenue $325 to $345 million; Adjusted EBITDA $125 to $140 million
- Net income
- 26
- Adjusted ebitda
- 58.7
- Melinta revenue
- 35.8
- Defencath revenue
- 66.1
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.